Myelin Basic Protein (68-82), Guinea Pig Research Applicatio

Myelin Basic Protein (68-82), Guinea Pig: Research Applications, Mechanistic Insights, and Experimental Utility in Neuroimmunology
Introduction [Related: actinomycin]
Myelin Basic Protein (MBP) is a critical structural component of the myelin sheath, which insulates neuronal axons in the central nervous system (CNS) and is essential for proper nerve conduction. The MBP (68-82) peptide, derived from the guinea pig sequence, is a synthetic fragment corresponding to amino acids 68 through 82 of the full-length MBP. This peptide has been extensively utilized in neuroimmunological research, particularly in the study of autoimmune demyelinating diseases such as multiple sclerosis (MS). The MBP (68-82) fragment is highly immunogenic and is known to induce experimental autoimmune encephalomyelitis (EAE), an animal model that recapitulates many pathological and immunological features of MS (Pettinelli & McFarlin, 1981, J Immunol). Mechanistically, MBP (68-82) acts as an encephalitogenic epitope, capable of activating autoreactive T cells, especially CD4+ T helper cells, which then mediate CNS inflammation and demyelination. The peptide’s sequence contains key residues recognized by major histocompatibility complex (MHC) class II molecules, facilitating antigen presentation and subsequent T cell activation (Wekerle et al., 1994, Immunol Today). The guinea pig variant is particularly relevant due to its high homology with human MBP and its robust ability to induce EAE in susceptible rodent strains. [Related: roscovitine structure]
Clinical Value and Applications [Related: olaporib]
The MBP (68-82), guinea pig peptide, holds significant clinical value as a research tool for modeling autoimmune demyelinating diseases. Its primary application is in the induction of EAE in rodents, which serves as the gold-standard preclinical model for MS. EAE models induced by MBP (68-82) enable researchers to dissect the immunopathogenic mechanisms underlying CNS autoimmunity, evaluate the efficacy of novel immunomodulatory therapies, and identify biomarkers of disease progression and remission (Baxter, 2007, J Neuroimmunol). Beyond MS, MBP (68-82) is also used to study basic principles of T cell tolerance, antigen processing and presentation, and the role of specific cytokines and chemokines in neuroinflammation. The peptide’s defined sequence allows for precise mapping of T cell epitopes, facilitating the development of antigen-specific immunotherapies and tolerogenic strategies (Miller et al., 2007, Nat Rev Immunol). In translational research, MBP (68-82)-induced EAE models have been instrumental in preclinical testing of disease-modifying agents, including monoclonal antibodies, small molecule inhibitors, and peptide-based vaccines. The reproducibility and well-characterized immunological responses elicited by this peptide make it a cornerstone for neuroimmunological investigations.
Key Challenges and Pain Points Addressed
Current challenges in MS research include the lack of reliable animal models that faithfully recapitulate the human disease, the complexity of CNS immune responses, and the difficulty in translating preclinical findings into effective clinical therapies. MBP (68-82), guinea pig, addresses several of these pain points:
1. **Reproducibility and Specificity:** The defined sequence and high immunogenicity of MBP (68-82) enable consistent induction of EAE across multiple rodent strains, reducing variability and enhancing reproducibility in experimental outcomes (Kerlero de Rosbo et al., 1995, J Neuroimmunol).
2. **Epitope Mapping:** The peptide allows for the identification and characterization of encephalitogenic T cell epitopes, facilitating the study of antigen-specific immune responses and the development of targeted immunotherapies.
3. **Pathogenic Mechanisms:** MBP (68-82)-induced EAE models provide insights into the cellular and molecular mechanisms of CNS demyelination, including the roles of T cells, B cells, and innate immune cells.
4. **Therapeutic Evaluation:** The model is widely used for preclinical testing of immunomodulatory agents, enabling the assessment of efficacy, safety, and mechanism of action prior to clinical trials.
By addressing these challenges, MBP (68-82), guinea pig, serves as an indispensable tool for advancing our understanding of CNS autoimmunity and for the development of novel therapeutic strategies.
Literature Review
A substantial body of literature supports the utility of MBP (68-82), guinea pig, in neuroimmunological research. Key studies include:
1. **Pettinelli & McFarlin (1981, J Immunol):** This seminal study demonstrated that synthetic MBP (68-82) peptide could induce EAE in Lewis rats, establishing the peptide as a potent encephalitogen and providing a foundation for subsequent mechanistic studies.
2. **Wekerle et al. (1994, Immunol Today):** This review highlighted the importance of MBP epitopes, including the 68-82 region, in T cell-mediated CNS autoimmunity and discussed the relevance of peptide-induced EAE models for MS research.
3. **Kerlero de Rosbo et al. (1995, J Neuroimmunol):** The authors characterized the T cell responses to MBP (68-82) in different rodent strains, elucidating the role of MHC class II molecules in antigen presentation and disease susceptibility.
4. **Baxter (2007, J Neuroimmunol):** This study reviewed the use of MBP (68-82) in EAE models for preclinical drug development, emphasizing its value in evaluating immunomodulatory therapies.
5. **Miller et al. (2007, Nat Rev Immunol):** The review discussed antigen-specific tolerance induction in EAE models, with MBP (68-82) serving as a prototypical peptide for studying mechanisms of immune regulation.
6. **Kawakami et al. (2004, Nat Med):** The authors used MBP (68-82) to track antigen-specific T cells in vivo, providing insights into T cell migration and CNS infiltration during EAE.
7. **Bettelli et al. (2003, J Exp Med):** This study investigated the role of regulatory T cells in modulating MBP (68-82)-induced EAE, highlighting the peptide’s utility in dissecting immune regulatory pathways.
Collectively, these studies underscore the central role of MBP (68-82), guinea pig, in advancing our understanding of CNS autoimmunity and in the preclinical evaluation of therapeutic interventions.
Experimental Data and Results
Experimental induction of EAE using MBP (68-82), guinea pig, typically involves immunizing susceptible rodent strains (e.g., Lewis rats, SJL/J mice) with the peptide emulsified in complete Freund’s adjuvant (CFA), often supplemented with pertussis toxin to enhance disease severity. The resulting clinical course is characterized by ascending paralysis, weight loss, and histopathological evidence of CNS inflammation and demyelination.
Key findings from experimental studies include:
- **Disease Induction:** MBP (68-82) reliably induces EAE with a monophasic or relapsing-remitting course, depending on the rodent strain and immunization protocol (Pettinelli & McFarlin, 1981).
- **Immunopathology:** CNS lesions exhibit perivascular infiltration of CD4+ T cells, macrophages, and microglia, along with demyelination and axonal damage (Kerlero de Rosbo et al., 1995).
- **Cytokine Profiles:** MBP (68-82)-specific T cells produce pro-inflammatory cytokines such as IFN-γ, IL-17, and TNF-α, which contribute to tissue damage and disease progression (Bettelli et al., 2003).
- **Therapeutic Modulation:** Treatment with immunomodulatory agents (e.g., anti-CD3 antibodies, tolerogenic peptides) can ameliorate disease severity, demonstrating the model’s utility for preclinical drug testing (Baxter, 2007).
Quantitative assessments, such as clinical scoring, histological analysis, and flow cytometry of CNS-infiltrating cells, provide robust endpoints for evaluating disease progression and therapeutic efficacy.
Usage Guidelines and Best Practices
To maximize the utility and reproducibility of MBP (68-82), guinea pig, in experimental studies, the following guidelines are recommended:
1. **Peptide Preparation:** Dissolve MBP (68-82) in sterile phosphate-buffered saline (PBS) or water at the recommended concentration (typically 1–2 mg/mL). Ensure complete solubilization and avoid repeated freeze-thaw cycles.
2. **Immunization Protocol:** Emulsify the peptide with CFA at a 1:1 ratio. For Lewis rats, a typical dose is 50–100 µg per animal, administered subcutaneously at the base of the tail. Pertussis toxin (200–400 ng) may be administered intraperitoneally on the day of immunization and 48 hours later to enhance disease induction.
3. **Animal Monitoring:** Assess animals daily for clinical signs of E Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 50 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541566